HyACT entrains chemotherapeutics in its ‘gel-like’ structure. These nanoparticles are transported around the body in the vasculature, extruding out of the leaky blood vessels found close to cancer cells. The HyACT particles form an extracellular drug depot specifically around cancer cells. HyACT binds specifically to its native target, activated CD44, on the surface of cancer cells, which triggers the internalisation of the HyACT nanoparticle, transporting the chemotherapeutic into the cancer cell. This structure is then broken down by the cell releasing the chemotherapeutic and HyACT within the cancer cell, causing cell death. Finally, the HyACT drug depot allows for this cycle to occur multiple times in parallel, further increasing the effectiveness of chemotherapeutics.